Review

data analysis software (Copley Scientific)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Copley Scientific data analysis software
Data Analysis Software, supplied by Copley Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/analysis+software/analysis+data+software/pmc13279920-216-9-13
Average 86 stars, based on 1 article reviews

data analysis software - by Bioz Stars, 2026-10

86/100 stars

Images

Standard Deviation:

Article Title: Inhaled nintedanib dry powder formulation for the treatment of idiopathic pulmonary fibrosis: Pharmacodynamic and pharmacokinetic study.
Article Snippet: Nintedanib has been clinically proven to slow the progression of idiopathic pulmonary fibrosis (IPF); however, its therapeutic utility is limited by the side effects resulting from extensive tissue distribution following oral administration.. To minimize systemic exposure and related adverse effects, an inhalable dry powder formulation of nintedanib was developed to directly deliver the drug to the lung.. The spray-dried formulation of nintedanib (SD-NTB), incorporating leucine as a dispersion enhancer, was successfully prepared, achieving favorable in vitro aerodynamic performance.

Article Title: Plasminogen-cyclodextrin aerosol for ARDS: activity retention in simulated oxygen therapy and inflammation-triggered clot lysis.
Article Snippet: Acute Respiratory Distress Syndrome (ARDS) involves intense pulmonary inflammation, endothelial damage, and fibrin accumulation, often requiring oxygen therapy.. Plasminogen (PLG), a fibrinolytic zymogen, has therapeutic potential for resolving fibrin deposits in the lungs but is vulnerable to oxidative degradation during aerosolization.. This study presents a clinically feasible inhalable formulation of PLG complexed with hydroxypropyl-β-cyclodextrin (HP-β-CD), intended to preserve enzymatic function during nebulization under oxygenrich conditions.

Article Title: Novel diffusion-dominated mixing for dry powder inhalations development: implementation and mechanistic insights.
Article Snippet: The Hummer acoustic resonance mixer (HAM) leverages high-frequency acoustic resonance to enable a novel mechanical shear-free mixing.. This mixing technology induces diffusion-dominated mixing and localized pseudoconvective particle motion, minimizing drug loss and reducing shear damage to particles.. This dual mechanism promotes efficient dispersion of micronized drug particles and ensures uniform drug-carrier adhesion, offering significant advantages for developing dry powder inhalations (DPIs).

Software:

Article Title: The development of ciclesonide dry powder inhalation and preliminary in vivo pharmacokinetic studies in rats
Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

Article Title: Fucose-tobramycin sponge-like microparticles to treat pulmonary Pseudomonas aeruginosa infections in a lectin-competitive approach.
Article Snippet: .. The collected data were analyzed utilizing the Copley inhalation test data analysis software version 3.10 (Copley Scientific Ltd, Nottingham, UK), which encompassed the assessment of emitted dose (ED), fine particle fraction (FPF), and mass median aerodynamic diameter (MMAD). ..

Article Title: Factors Influencing the Dispersibility of Glycopyrronium Bromide and Indacaterol Maleate - Combined In Vitro and In Silico Study.
Article Snippet: .. Aerodynamic parameters were calculated using CITDAS (Copley Inhaler Data Analysis Software, UK, version 3.10), a commercial data‐processing software provided by Copley Scientific, Nottingham, UK. ..

Article Title: Engineered Spray-Dried PLGA-PEG Dual-Coated Micelles with Lactose/Trehalose Matrices for Pulmonary Doxorubicin Delivery: Achieving Sustained Release and Improved Aerosol Performance in NSCLC Therapy
Article Snippet: inadequate tumor selectivity, and dose-dependent toxicities, most notably life-threatening cardiotoxicity and myelosuppression [2, 3].. Inhalable nanocarrier systems represent a promising strategy to overcome these limitations by leveraging the lungs as both the primary disease site and a directly accessible portal for localized therapy.. This approach aims to maximize intratumoral drug deposition while minimizing systemic exposure and associated toxicity [4, 5].

Aerosol:

Analysis:

Similar Products

Image Search Results

$Physical attributes of naturally aged mice were enhanced following mGFD‐CD3 treatment. (A) Maximal walking speed, treadmill endurance, hanging endurance, and grip strength of naturally aged mice treated with mCD3 or mGFD‐CD3 were recorded at 6 months after the first infusion ( n = 5 mice per condition). (B) H&E staining of gastrocnemius collected from mice treated with mCD3 or mGFD‐CD3, sampled 6 months after the first infusion. Scale bar, 50 μm. Relative cell areas in the gastrocnemius were quantified using Image J ( n = 5 mice per condition). (C) Representative micro‐CT images of the distal femurs of the mice treated with mCD3 or mGFD‐CD3 at 6 months after the first infusion. The relative bone volume fraction (BV/TV) of cancellous bone in the distal femur was quantified for each sample and analyzed by Imaris image analysis software ( n = 5 mice per condition). (D) The percentages of total lean mass and total adipose mass and the adipose mass/lean mass ratio of naturally aged mice treated with mCD3 or mGFD‐CD3 6 months after the first infusion were recorded using InAlyzer software ( n = 5 mice per condition). (E) (left) Micro‐CT images of SAT and bone of the naturally aged mice treated with mCD3 or mGFD‐CD3 were recorded 6 months after the first infusion. Green, SAT; red, bone. (right) Quantification of the adipose tissue of mice based on the micro‐CT images ( left ). Data were normalized to mouse body weight ( n = 5 mice per condition). (F) Basal glucose levels after 12 h of starvation in mice treated with mCD3 or mGFD‐CD3 at 6 months after the first infusion ( n = 5 mice per condition). (G) ( upper ) Levels of glucose before (0 min) and after the intraperitoneal administration of glucose (2 g per kg body weight) (samples as per in (f)). ( lower ) Area under the curve (AUC) for the results from (g) ( n = 5 mice per condition). The mouse experiments are representative results from two independent experiments. Data are presented as mean ± SD and analyzed by one‐way ANOVA followed by Tukey's multiple comparisons test (A–G). * p ≤ 0.05; ** p ≤ 0.01.$

Journal: Aging Cell

Article Title: uPAR ‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor

doi: 10.1111/acel.70742

Figure Lengend Snippet: Physical attributes of naturally aged mice were enhanced following mGFD‐CD3 treatment. (A) Maximal walking speed, treadmill endurance, hanging endurance, and grip strength of naturally aged mice treated with mCD3 or mGFD‐CD3 were recorded at 6 months after the first infusion ( n = 5 mice per condition). (B) H&E staining of gastrocnemius collected from mice treated with mCD3 or mGFD‐CD3, sampled 6 months after the first infusion. Scale bar, 50 μm. Relative cell areas in the gastrocnemius were quantified using Image J ( n = 5 mice per condition). (C) Representative micro‐CT images of the distal femurs of the mice treated with mCD3 or mGFD‐CD3 at 6 months after the first infusion. The relative bone volume fraction (BV/TV) of cancellous bone in the distal femur was quantified for each sample and analyzed by Imaris image analysis software ( n = 5 mice per condition). (D) The percentages of total lean mass and total adipose mass and the adipose mass/lean mass ratio of naturally aged mice treated with mCD3 or mGFD‐CD3 6 months after the first infusion were recorded using InAlyzer software ( n = 5 mice per condition). (E) (left) Micro‐CT images of SAT and bone of the naturally aged mice treated with mCD3 or mGFD‐CD3 were recorded 6 months after the first infusion. Green, SAT; red, bone. (right) Quantification of the adipose tissue of mice based on the micro‐CT images ( left ). Data were normalized to mouse body weight ( n = 5 mice per condition). (F) Basal glucose levels after 12 h of starvation in mice treated with mCD3 or mGFD‐CD3 at 6 months after the first infusion ( n = 5 mice per condition). (G) ( upper ) Levels of glucose before (0 min) and after the intraperitoneal administration of glucose (2 g per kg body weight) (samples as per in (f)). ( lower ) Area under the curve (AUC) for the results from (g) ( n = 5 mice per condition). The mouse experiments are representative results from two independent experiments. Data are presented as mean ± SD and analyzed by one‐way ANOVA followed by Tukey's multiple comparisons test (A–G). * p ≤ 0.05; ** p ≤ 0.01.

Article Snippet: 3D image analysis was performed with Imaris image analysis software (version 10.1.0).

Techniques: Staining, Micro-CT, Analysis, Software, Tissue